Skip to main content

Table 1 Clinical characteristics and blood laboratory tests of AS patients and controls (excluding participants with positive urinary cultures - two in the AS group and one in the control group)

From: An investigation about chronic prostatitis in ankylosing spondylitis

  AS (n = 43) Controls (n = 44) p
Age (years) 52.5 ± 10.0 52.8 ± 12.1 0.882
Disease duration (years) 12.4 ± 6.9   
Anti-TNF treatment 35 (86.0%)   
BASDAI 4.9 ± 1.7   
ASDAS 2.7 ± 0.6   
NIH-CPSI 4.0 [1.0–12.0] 5.0 [1.0–8.5] 0.944
NIH-CPSI (Pain Domain) ≥ 4 10 (23.3%) 10 (22.7%) 0.953
NIH-CPSI (Pain Domain) ≥ 8 6 (14.0%) 5 (11.4%) 0.716
IPSS 6 [2.5–13.5] 2.5 [0.0–12.0] 0.105
IPSS > 8 14 (32.6%) 13 (29.5%) 0.499
PSA (ng/mL) 1.2 ± 1.1 1.8 ± 2.0 0.324
CRP (mg/L) 3.2 [2.8–3.3] 2.3 [1.0–2.6] 0.011*
ESR (mm/h) 4 [3–5] 3 [2–5] 0.857
Uric acid (mg/dL) 5.8 ± 1.3 5.5 ± 1.2 0.624
  1. ASDAS Ankylosing spondylitis disease activity score, AS Ankylosing spondylitis, BASDAI Bath ankylosing spondylitis disease activity index, NIH-CPSI National Institutes of Health - Chronic Prostatitis Symptom Index, IPSS International Prostate Symptom Score, PSA Prostate-specific antigen, TNF Tumor necrosis factor, CRP C-reactive protein, ESR Erythrocyte sedimentation rate. Data are presented as mean ± standard deviation (for normally distributed data), median [interquartile range] for non-parametric data